|
2003 AŞILAMA ORANLARI |
||||||||||||||||||||
|
Hedef Nüfus |
DBT /OPV 1 | DBT /OPV 2 | DBT /OPV 3 | KIZAMIK | BCG | HEPATİT B 1 | HEPATİT B 2 | HEPATİT B 3 | TT1 | TT2+ | ||||||||||
| DOZ | ORAN | DOZ | ORAN | DOZ | ORAN | DOZ | ORAN | DOZ | ORAN | DOZ | ORAN | DOZ | ORAN | DOZ | ORAN | DOZ | ORAN | DOZ | ORAN | |
| 3104 | 2499 | 81% | 2451 | 79% | 2397 | 77% | 2526 | 81% | 2523 | 81% | 2912 | 94% | 2695 | 87% | 2531 | 82% | 1662 | 54% | 2306 | 74% |
|
2004 AŞILAMA ORANLARI |
||||||||||||||||||||
|
Hedef Nüfus |
DBT /OPV 1 | DBT /OPV 2 | DBT /OPV 3 | KIZAMIK | BCG | HEPATİT B 1 | HEPATİT B 2 | HEPATİT B 3 | TT1 | TT2+ | ||||||||||
| DOZ | ORAN | DOZ | ORAN | DOZ | ORAN | DOZ | ORAN | DOZ | ORAN | DOZ | ORAN | DOZ | ORAN | DOZ | ORAN | DOZ | ORAN | DOZ | ORAN | |
| 2858 | 2537 | 89% | 2496 | 87% | 2617 | 92% | 2576 | 90% | 2582 | 90% | 1907 | 67% | 2995 | 115% | 2741 | 96% | 1669 | 58% | 2318 | 82% |